Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in systemic juvenile idiopathic arthritis (sJIA)
CTR20181512Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib in systemic juvenile idiopathic arthritis (SJIA), sponsored by Pfizer. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on CTR20181512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181512.